AdaptHealth, a major U.S. provider of home medical equipment and respiratory care, delivered a better-than-expected third quarter, and analysts at RBC Capital Markets say the company's previously struggling West Coast contract is finally starting to pay off. The investment bank estimates that the contract's profit margin swung to roughly 10% in the third quarter, up from a negative 4% in the second quarter, and ended September at around 14%.
The improvement, according to RBC, stems from two main factors: lower labor costs and what the bank calls "normalized utilization." In plain terms, the company is spending less on staff and seeing more predictable patterns in how much equipment and service patients actually use. That matters because the West Coast contract is what's known as a capitated agreement, meaning AdaptHealth receives a fixed payment per patient regardless of how much care or equipment that patient ends up needing.
Why the margin swing matters
Under a capitated model, revenue is largely predetermined. The company's profitability depends almost entirely on whether it can deliver care and equipment for less than that fixed payment. When patient usage swings wildly, costs can spike and margins get squeezed. When usage settles down, as RBC says it did in the third quarter, the company can better match its spending to the revenue it's receiving.
RBC also pointed to a roughly 12% reduction in headcount since the end of the second quarter as a key driver of lower per-patient costs. Fewer employees means lower payroll expenses, which directly boosts the bottom line on a contract where revenue isn't growing.
The bank also noted an $8 million recovery in the third quarter tied to a manufacturer rebate agreement, which added a one-time boost to results. And while AdaptHealth has some exposure to a product recall from Medline, a major medical supplies manufacturer, RBC said that exposure looks manageable. Revenue from the recalled products represents only a low-single-digit percentage of the company's total, and alternative suppliers are available, so the disruption should be limited.
What it means for investors
For everyday investors, the key takeaway is that AdaptHealth's West Coast contract—long a drag on the company's performance—appears to be turning a corner. RBC's estimate of a roughly 14% exit margin in September is a quick check on the economics of that contract. If those margin levels prove repeatable, the company could be on a clearer path to the 20% margin RBC expects by the fourth quarter of 2027.
That longer-term target is important because it suggests the improvement isn't just a one-off quarter. Under a capitated model, once costs drop below the fixed payment rate, each additional efficiency gain tends to lift profit margins more than it would under a traditional pay-per-service arrangement. That's why the sequence RBC highlighted—from negative 4% in the second quarter to about 10% in the third, and roughly 14% by late September—is so significant.
RBC kept an "outperform" rating on AdaptHealth's stock and maintained an $8 price target. That target implies meaningful upside from current levels, but it also reflects the "execution risk" that has kept the stock trading below published targets. If the company can sustain these margin improvements, that risk discount could narrow.
AdaptHealth operates in the home healthcare space, a sector that has seen steady demand as more patients receive care at home rather than in hospitals. The company's broader business includes oxygen therapy, sleep apnea equipment, and other respiratory products. The West Coast contract has been a sore spot for the company in recent quarters, so this turnaround is a notable positive.
Investors should keep an eye on whether the margin improvement holds up in the coming quarters. A single quarter of good numbers can be encouraging, but the real test is whether AdaptHealth can maintain cost discipline and keep utilization stable. If it can, the path to that 20% margin becomes more credible, and the stock could re-rate higher.
For context, other companies in the healthcare and equipment space have faced similar challenges with capitated contracts, where fixed payments require tight cost control. The ability to manage labor costs and patient usage is often the difference between profit and loss. AdaptHealth's recent progress suggests it's learning to do that on the West Coast.
As always, no investment decision should be based solely on one analyst's view. But for those following AdaptHealth, the RBC note offers a clear, data-driven reason to be more optimistic about the company's trajectory.
